(19) World Intellectual Property **Organization**

International Bureau



(43) International Publication Date 12 February 2004 (12.02.2004)

PCT

(10) International Publication Number WO 2004/012503 A3

(51) International Patent Classification⁷: A61K 35/12, A61P 21/00

C12N 5/08,

(74) Agents: HERTOGHE, Kris et al.; Bird Goën & Co.,

AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

(21) International Application Number:

PCT/EP2003/009008

(22) International Filing Date: 30 July 2003 (30.07.2003)

(25) Filing Language:

English

(26) Publication Language:


English

(30) Priority Data: 60/399,745

30 July 2002 (30.07.2002)

- (71) Applicant (for all designated States except US): TIGENIX N.V. [BE/BE]; Technologielaan 3, B-3001 Leuven (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DE BARI, Cosimo

- Klein Dalenstraat 42 A, B-3020 Winksele (BE). (81) Designated States (national): AE, AG, AL, AM, AT, AU,
- CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW. (84) Designated States (regional): ARIPO patent (GH, GM,
- KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).



from joint tissue, in a mouse model of skeletal muscle regeneration. MPCs participated in the regeneration process by long-term persistence and contribution to the compartment of myonuclei and the pool of functional satellite cells. When injected into dystrophic muscles of immunosuppressed mdx mice, human MPCs restored dystrophin in some fibers, and rescued the expression of mouse mechano-growth factor. In addition, the human MPCs derived from synovial membrane were injected into infarcted myocardial muscle. The MPCs engrafted successfully, underwent proliferation and differentiation leading to functional recovery and maintenance of the cardiac muscle. MPCs represent an alternative source of myogenic cells in therapeutic approaches for postnatal skeletal and cardiac muscle repair.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



INTERNATIONAL SEARCH REPORT



International Application No PCT/EP 03/09008

| A. CLASSIF IPC 7 | FICATION OF SUBJECT MATTER C12N5/08 A61K35/12 A61P21/00 |) | | | |
|---|---|--|-----------------------|--|--|
| According to International Patent Classification (IPC) or to both national classification and IPC | | | | | |
| B. FIELDS | | | | | |
| Minimum do | cumentation searched (classification system followed by classification C12N | symbols) | | | |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched | | | | | |
| | ata base consulted during the international search (name of data base ternal, WPI Data, PAJ, MEDLINE, BIOS | · | CHEM ABS Data | | |
| C. DOCUME | ENTS CONSIDERED TO BE RELEVANT | ···· | | | |
| Category ° | Citation of document, with indication, where appropriate, of the relev | ant passages | Relevant to claim No. | | |
| X | | ial 1942, graph 3 - agraph 2 ragraph 1 | 1-27, 32-35 | | |
| X Furth | X Further documents are listed in the continuation of box C. Patent family members are listed in annex. | | | | |
| "T" later document published after the international filing date or priority date and not in conflict with the application but clied to understand the principle or theory underlying the invention filing date or priority date and not in conflict with the application but clied to understand the principle or theory underlying the invention filing date or priority date and not in conflict with the application but clied to understand the principle or theory underlying the invention filing date or priority date and not in conflict with the application but clied to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone of document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is cannot be considered to involve an inventive step when the document is cannot be considered to involve an inventive step when the document is cannot be considered to involve an inventive step when the document is combined with one or more other such document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "B" document published after the international filling date or priority date and not in conflict with the application but clied to understand the principle or theory underlying the claimed invention cannot be considered novel or cannot be considered | | eory underlying the claimed invention to considered to coment is taken alone claimed invention wentive step when the person skilled family | | | |
| 14 January 2004 | | 1 0. 05. 2004 | | | |
| Name and r | mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswljk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3018 | Authorized officer Sitch, W | | | |

1



INTERNATIONAL SEARCH REPORT

International Application No PCT/EP 03/09008

| Category ° | ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-------------------------|
| Jaleyory * | Change of the property of the passages | Delevant to Gailli 140. |
| x | DE BARI C ET AL: "Human synovial membrane-derived mesenchymal stem cells for skeletal muscle repair" ONCOLOGY RESEARCH, vol. 12, no. 6-7, 2001, page 284, XP008026328 2001 Millennium International Conference of Molecular and Tumor Biology; Santorini, Greece; September 02-07, 2001 ISSN: 0965-0407 abstract 31 | 1-27, 32-35 |
| x | DE BARI C ET AL: "Human mesenchymal stem cells from synovial membrane contribute to skeletal muscle repair in vivo" CLINICAL RHEUMATOLOGY, vol. 20, no. 5, 2001, page 400, XP001184115 5th Belgian Congress on Rheumatology; Hasselt, Belgium; September 27-29, 2001 ISSN: 0770-3198 abstract RA11 | 1-27, 32-35 |
| P,X | DE BARI COSIMO ET AL: "Skeletal muscle repair by adult human mesenchymal stem cells from synovial membrane." JOURNAL OF CELL BIOLOGY, vol. 160, no. 6, 17 March 2003 (2003-03-17), pages 909-918, XP002266868 ISSN: 0021-9525 page 909 abstract | 1-27, 32-35 |
| P,X | DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; May 2003 (2003-05), VANDENABEELE F ET AL: "Morphological and immunocytochemical characterization of cultured fibroblast-like cells derived from adult human synovial membrane." XP002266869 Database accession no. PREV200300404606 abstract & ARCHIVES OF HISTOLOGY AND CYTOLOGY, vol. 66, no. 2, May 2003 (2003-05), pages 145-153, ISSN: 0914-9465 | 1-27, 32-35 |



INTERNATIONAL SEARCH REPORT

International application No. PCT/EP 03/09008

| Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet) | _ | | | | |
|---|---|--|--|--|--|
| This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: | | | | | |
| 1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: | | | | | |
| Although claims 25-27, 32, 33 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. | | | | | |
| 2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: | | | | | |
| 3. Claims Nos.: | | | | | |
| 3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). | | | | | |
| Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet) | _ | | | | |
| This International Searching Authority found multiple inventions in this international application, as follows: | _ | | | | |
| | | | | | |
| see additional sheet | | | | | |
| | | | | | |
| | | | | | |
| 1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims. | | | | | |
| 2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. | | | | | |
| 3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report | | | | | |
| covers only those claims for which fees were paid, specifically claims Nos.: | | | | | |
| | | | | | |
| | | | | | |
| 4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: | | | | | |
| 1-27, 32-35 | | | | | |
| | | | | | |
| Remark on Protest The additional search fees were accompanied by the applicant's protest. | | | | | |
| No protest accompanied the payment of additional search fees. | | | | | |
| | | | | | |



International Application No. PCT/ EP 03/09008

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 25-27, 32, 33 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-27, 32-35

Compositions, in particular pharmaceutical compositions, comprising the joint tissue derived muscle precursor / progenitor cell population; use thereof in the manufacture of pharmaceutical compositions, therapeutic uses thereof

2. claims: 28-31

Method of selecting muscle precursor cells via contacting a joint derived cell population with a binding substance for various markers of the cell population